Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL13Ra2-BBz-EGFRt CAR-T cells
- Development stage
- Unknown
- Lead developer
- City of Hope
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intracranial, Intrathecal, Intracerebroventricular
01
Overview
**IL13Ra2-BBz-EGFRt CAR-T cells** are an investigational autologous **CAR-T cell therapy** engineered to target **interleukin-13 receptor alpha 2**, a tumor-associated antigen highly expressed in glioblastoma and other high-grade gliomas. The construct name indicates an **IL13Rα2-directed CAR** incorporating a **4-1BB costimulatory domain** and **CD3 zeta signaling domain**, together with a truncated **EGFRt** marker/suicide tag commonly used for cell tracking and potential cetuximab-mediated ablation. This program has been developed at **City of Hope** for **recurrent or refractory glioblastoma**, including locoregional CNS delivery approaches, and remains an early-stage investigational cell therapy platform for solid tumors.
- Other names
- IL13Ralpha2-CAR T cellsIL-13Ralpha2-CAR T cellsIL 13Ralpha2-CAR T cellsIL13Rα2-CAR T cellsIL13Rα2-BBz-EGFRt CAR-T cellsIL13RA2 CAR-T cellsIL-13RA2 CAR-T cellsIL 13RA2 CAR-T cells
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)IL13RA2 (Interleukin-13 receptor subunit alpha 2)
Beyond the preview
Go deeper on IL13Ra2-BBz-EGFRt CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL13Ra2-BBz-EGFRt CAR-T cells.